Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis-Reference-Cited by-同舟云学术

Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis

Published:2017-12-04 Issue:4 Volume:47 Page:516-525
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Mettke F.¹,Schlevogt B.²,Deterding K.¹,Wranke A.¹,Smith A.³,Port K.¹,Manns M. P.¹⁴⁵,Vogel A.¹,Cornberg M.¹⁴,Wedemeyer H.¹⁴⁵^ORCID

Affiliation:

1. Department of Gastroenterology, Hepatology and Endocrinology; Hannover Medical School; Hannover Germany

2. Department of Transplantation Medicine; University of Muenster; Muenster Germany

3. Institute of Biostatistics; Hannover Medical School; Hannover Germany

4. Integrated Research and Treatment Center - Transplantation (IFB-Tx); Hannover Medical Hannover; Hannover Germany

5. Partner Site Hannover-Braunschweig; German Center for Infection Research (DZIF); Germany

Funder

Deutsches Zentrum für Infektionsforschung

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14427/fullpdf

Reference33 articles.

1. Towards interferon-free treatment for all HCV genotypes;Wedemeyer;Lancet,2015

2. From non-A, non-B hepatitis to hepatitis C virus cure;Pawlotsky;J Hepatol,2015

3. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies;Deterding;Aliment Pharmacol Ther,2015

4. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis;Foster;J Hepatol,2016

5. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir;Younossi;J Hepatol,2015

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies;Journal of the Canadian Association of Gastroenterology;2024-08-09

2. Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct‐acting antiviral agents;Journal of Gastroenterology and Hepatology;2024-04-11

3. Direct-acting antivirals failed to reduce the incidence of hepatocellular carcinoma occurrence in hepatitis C virus associated cirrhosis: A real-world study;World Journal of Hepatology;2024-01-27

4. Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-09-20

5. Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response;Journal of the Chinese Medical Association;2023-07-19